ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 76 - 90 of 5996 products
CStone Reports Positive Early Results from Phase I Trial of ROR1 ADC
$5.00
Available
Tyligand Starts US Trial of KRAS G12D Inhibitor for Solid Tumor Cancers
$5.00
Available
Degron Partners Molecular Glue Degraders with Takeda in $1.2 Billion Deal
$5.00
Available
Nona Bio Signs $604 Million License to Discover mAbs for AstraZeneca
$5.00
Available
AstraZeneca Says China is Important Source for Innovative Drug Development
$5.00
Available
Innovent’s IGF-1R Antibody NDA Under China Review for Thyroid Eye Disease
$5.00
Available
RemeGen Completes Enrollment in Two Phase III Trials for Autoimmune Diseases
$5.00
Available
Hengrui Sells GLP-1 Portfolio Rights to Startup in $6 Billion Deal
$5.00
Available
AstraZeneca Plans $1.5 Billion ADC Manufacturing Plant in Singapore
$5.00
Available
Erasca In-licenses Two China RAS Candidates in Two Deals Worth $349 Million
$5.00
Available
Eisai Expects Big Improvement in Sales for Alzheimer’s Therapy in 2024
$5.00
Available
Beimei Pharma In-licenses Acne Therapy from Sol-Gel in $15 Million Deal
$5.00
Available
InnoCare Completes Phase II Enrollment of TYK2 Inhibitor for Psoriasis
$5.00
Available
Takeda to Option Alzheimer’s Therapy from AC Immune in $2.2 Billion Deal
$5.00
Available
Ractigen Says China IND Approved for siRNA Candidate that Targets ALS
$5.00
Available